Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Non-Small Cell Lung Cancer
BIOLOGICAL: Ivonescimab Injection|BIOLOGICAL: Pembrolizumab Injection
Overall Survival (OS), Overall Survival (OS) in the ITT population, approximately 6 years|Progression Free Survival (PFS), Progression Free Survival (PFS) assessed by investigator based on RECIST V1.1, approximately 3 years
Adverse Event (AE), incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results, From the subject signs the ICF to 30 days (AE) and 90 days (SAE related to ivonescimab/pembrolizumab ) after the last dose of study treatment or initiation of other anticancer therapy, whichever occurs first, up to 2 years.
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.